Wspolczesna Onkologia-Contemporary Oncology

Scope & Guideline

Empowering Global Collaboration in Cancer Research

Introduction

Immerse yourself in the scholarly insights of Wspolczesna Onkologia-Contemporary Oncology with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageMulti-Language
ISSN1428-2526
PublisherTERMEDIA PUBLISHING HOUSE LTD
Support Open AccessYes
CountryPoland
TypeJournal
Convergefrom 2005 to 2024
AbbreviationWSPOLCZESNA ONKOL / Wspolczesna Onkol.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressKLEEBERGA 2, POZNAN 61-615, POLAND

Aims and Scopes

Wspolczesna Onkologia-Contemporary Oncology is dedicated to advancing the understanding and treatment of various cancers through innovative research and clinical studies. The journal emphasizes the integration of basic science with clinical applications, aiming to provide insights that can enhance patient care and therapeutic efficacy.
  1. Clinical Oncology Research:
    The journal focuses on clinical studies that evaluate treatment outcomes, safety profiles, and the efficacy of various cancer therapies, including chemotherapy, immunotherapy, and targeted therapies.
  2. Molecular and Cellular Oncology:
    Research on the molecular mechanisms underlying cancer development, progression, and metastasis is a core focus, including studies on gene expression, signaling pathways, and the tumor microenvironment.
  3. Translational Research:
    The journal supports translational research that bridges laboratory findings with clinical applications, aiming to translate scientific discoveries into effective treatment strategies for cancer patients.
  4. Patient-Centered Outcomes:
    There is a strong emphasis on studies that assess the psychosocial aspects of cancer care, including patient satisfaction, quality of life, and coping mechanisms, reflecting a holistic approach to oncology.
  5. Innovative Diagnostic Techniques:
    The journal publishes research on novel diagnostic methods, including imaging techniques and biomarker discovery, which are crucial for early detection and personalized treatment strategies.
Recent publications in Wspolczesna Onkologia-Contemporary Oncology indicate a shift towards several emerging themes that address contemporary challenges in oncology and reflect advancements in cancer research.
  1. Immunotherapy and Targeted Therapies:
    There is a growing trend towards research on immunotherapy and targeted treatments, reflecting the rapid advancements in these areas and their significance in improving patient outcomes.
  2. Molecular Profiling and Biomarkers:
    Emerging studies focus on the identification and validation of molecular biomarkers for cancer diagnosis, prognosis, and treatment responses, indicating a trend towards personalized medicine.
  3. Artificial Intelligence and Machine Learning in Oncology:
    The incorporation of AI and machine learning techniques for cancer detection, diagnosis, and treatment planning is gaining traction, highlighting the role of technology in modern oncology.
  4. Psycho-Oncology and Patient Wellbeing:
    Research addressing the psychosocial dimensions of cancer care, including the mental health of patients and their families, is increasingly prevalent, emphasizing the importance of a holistic approach to treatment.
  5. Real-World Evidence and Outcomes Research:
    There is a notable increase in studies utilizing real-world data to assess treatment outcomes and patient experiences, reflecting a shift towards understanding the effectiveness of interventions in everyday clinical practice.

Declining or Waning

Over the years, certain themes within Wspolczesna Onkologia-Contemporary Oncology have seen a decrease in emphasis, reflecting shifts in research priorities and the evolving landscape of oncology.
  1. Traditional Chemotherapy Studies:
    While still relevant, there has been a noticeable decline in studies focused solely on traditional chemotherapy regimens, as the field increasingly shifts towards personalized and targeted therapies.
  2. Epidemiological Studies:
    Research that primarily focuses on cancer epidemiology and incidence trends has become less prominent, likely due to a growing interest in molecular and therapeutic research.
  3. Case Reports and Single-Center Experiences:
    The frequency of case reports and single-center studies has decreased, suggesting a shift towards larger, multicenter studies that provide more generalizable results.
  4. Basic Science Research:
    There is a waning focus on basic science research unrelated to clinical applications, as the journal prioritizes studies that integrate laboratory findings with clinical implications.
  5. Complementary and Alternative Medicine:
    Interest in studies exploring complementary and alternative therapies appears to be declining, possibly due to a stronger emphasis on evidence-based conventional treatments.

Similar Journals

CANCER INVESTIGATION

Driving innovation in cancer studies for impactful discoveries.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Discover Oncology

Fostering a community of knowledge in oncology and endocrinology.
Publisher: SPRINGERISSN: Frequency: 1 issue/year

Discover Oncology, published by SPRINGER, is an influential journal based in Germany that focuses on the latest advancements in the fields of oncology and endocrinology. With an evolving scope that spans critical research from 2021 to 2024, this journal aims to provide a platform for innovative ideas and research findings that can significantly impact clinical practices. Although it currently holds a Q3 ranking in several Cancer Research and Endocrine category quartiles, its commitment to open access ensures that relevant knowledge is available to a wider audience, facilitating the exchange of ideas among researchers, professionals, and students. As evidenced by its growing presence in various medical spheres, including a Q2 ranking in Endocrinology and Diabetes, the journal plays a crucial role in advancing multidisciplinary research that integrates oncology with broader biological and medical parameters. For those in the field, Discover Oncology serves as both a resource and a community hub, encouraging collaboration and exploration of emerging findings that can lead to novel therapeutic approaches.

CELLULAR ONCOLOGY

Connecting Minds to Combat Cancer
Publisher: SPRINGERISSN: 2211-3428Frequency: 6 issues/year

CELLULAR ONCOLOGY is an esteemed open access journal published by SPRINGER since 2004, specializing in the dynamic field of oncological research. With its ISSN 2211-3428 and E-ISSN 2211-3436, this journal plays a pivotal role in disseminating cutting-edge findings and innovative methodologies that address cancer at the cellular level. The journal has consistently achieved high-impact recognition, currently holding a Q2 rating in Cancer Research and Q1 rankings in Medicine (miscellaneous), Molecular Medicine, and Oncology as of 2023. Furthermore, it ranks 56th in oncology medicine and 48th in cancer research according to Scopus, placing it firmly within the top echelons of its field. Published in the Netherlands, with an aim to connect scientists, clinicians, and practitioners worldwide, CELLULAR ONCOLOGY fosters a collaborative environment for researchers to share insights, enhance understanding, and advance treatments. The journal’s open access model ensures that ground-breaking research is freely available, facilitating greater visibility and impact within the scientific community and beyond.

Turk Onkoloji Dergisi-Turkish Journal of Oncology

Connecting researchers to transform cancer treatment and prevention.
Publisher: KARE PUBLISSN: 1300-7467Frequency: 4 issues/year

Turk Onkoloji Dergisi - Turkish Journal of Oncology, published by KARE PUBL, serves as a vital platform in the field of oncology, specifically catering to the Turkish-speaking research community and contributing to global discourse. With an ISSN of 1300-7467, this journal, which has been in circulation since 2007 and continues until 2024, recognizes the importance of advancing medical knowledge in cancer research through rigorous peer-reviewed articles. Although currently positioned in the Q4 category of oncology journals with a Scopus rank of #344 out of 404, the journal is dedicated to fostering significant research insights and innovative perspectives on cancer treatment and prevention. While it does not currently offer open access, its content is essential for professionals, researchers, and students aiming to enhance their understanding of oncology developments in Turkey and beyond. The Turkish Journal of Oncology not only aspires to improve the quality of cancer care but also strives to enhance collaboration among researchers, thereby influencing future oncology practices.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Unveiling Breakthroughs in Cancer Clinical Trials
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0277-3732Frequency: 12 issues/year

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.

South Asian Journal of Cancer

Illuminating breakthroughs in oncology and prevention.
Publisher: GEORG THIEME VERLAG KGISSN: 2278-330XFrequency: 4 issues/year

South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.

World Journal of Oncology

Advancing cancer research, one study at a time.
Publisher: ELMER PRESS INCISSN: 1920-4531Frequency: 12 issues/year

The World Journal of Oncology, published by ELMER PRESS INC, is a vibrant platform for disseminating groundbreaking research and advancements in the field of oncology. With its ISSN 1920-4531 and E-ISSN 1920-454X, this journal is dedicated to publishing high-quality studies that enhance our understanding of cancer and its treatment. The journal is recognized for its significant contributions, evidenced by its Q2 classification in both Cancer Research and Oncology categories in 2023, and accolades such as a Scopus rank of #126/404 in Medicine _ Oncology. Catering to the needs of researchers, professionals, and students, the World Journal of Oncology offers an essential resource for the latest scientific insights and clinical practices, ensuring the global oncology community remains informed and engaged. The journal operates under a selective publication model, maintaining rigor in peer review while facilitating knowledge sharing across converged years from 2014 to 2016 and 2020 to 2024, further establishing its importance in the ongoing fight against cancer.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Advancing cancer research through innovative insights.
Publisher: OXFORD UNIV PRESSISSN: 0368-2811Frequency: 12 issues/year

The Japanese Journal of Clinical Oncology, published by Oxford University Press, is a pivotal platform for advancing knowledge in the fields of cancer research, oncology, and related medical disciplines. Since its inception in 1971, this journal has contributed significantly to the dissemination of cutting-edge research and clinical practices, featuring a breadth of scholarly articles that cater to the needs of researchers, practitioners, and students alike. With an impact factor reflecting its robust reputation, the journal is ranked in the Q3 category for both Cancer Research and Oncology, and Q2 in Medicine (miscellaneous), and Radiology, Nuclear Medicine and Imaging as of 2023. These rankings, alongside the journal's Scopus rankings, signify its important role in the scientific community and its commitment to fostering innovative research. Although it is not an Open Access journal, the Japanese Journal of Clinical Oncology continues to provide valuable insights and educational resources, making it essential for anyone engaged in the fight against cancer.

Journal of Cancer Metastasis and Treatment

Advancing oncology through innovative research.
Publisher: OAE PUBLISHING INCISSN: 2394-4722Frequency: 1 issue/year

Journal of Cancer Metastasis and Treatment, published by OAE PUBLISHING INC, stands as a vital resource in the field of oncology, focusing on advancements and research pertaining to cancer metastasis and treatment methodologies. With an ISSN of 2394-4722 and an E-ISSN of 2454-2857, this journal aims to serve as a comprehensive platform for sharing innovative research, critical analyses, and novel findings from 2019 through 2024. As indexed in Scopus, it holds a notable Q3 ranking within its category, positioned at 240/404 and within the 40th percentile, thus reflecting its growing significance in the scientific community. Though currently not open access, the journal aspires to improve accessibility to pivotal oncology research, making it an essential tool for researchers, clinicians, and students keen on unraveling the complexities of cancer treatment and metastasis. Its commitment to promoting high-quality studies plays a crucial role in the ongoing quest to enhance patient care and outcomes in cancer treatment.

Cancers

Advancing cancer research for a healthier tomorrow.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.